Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes

British Journal of General Practice

Volumn 58, Issue 553, 2008, Pages 531-533

  Feher, Michael D ^a   Munro, Neil ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DAPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR ANTAGONIST; HORMONE RECEPTOR AFFECTING AGENT; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SRT 501; SULFONYLUREA; VILDAGLIPTIN;

CLINICAL TRIAL; CONSENSUS; DIET; DRUG CHOICE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATIENT EDUCATION; PRACTICE GUIDELINE; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 49149121982     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp08X319684     Document Type: Editorial

References (16)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131):854-865.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
3. National Collaborating Centre for Chronic Conditions. type 2 diabetes. National clinical guidelines for managment in primary and secondary care (update). http://www.nice.org.uk/nicemedia/pdf/ CG66diabetesfullguideline.pdf (accessed 14 Jul 2008).
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-2471.
5. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772-1780.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853,
7. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
8. Levy JC. Therapeutic intervention in the GLP-1 pathway in type 2 diabetes. Diabet Med 2006; 23(Suppl 1): 14-19.
9. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008; 25(2): 152-156.
10. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30(6): 1487-1493.
11. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2): CD006739.
12. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-2572.
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545-2559.
14. Jiang W J. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 2008: doi:10.1016/ j.bbrc_2008.06.048.
15. Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11(8): 959-967.
16. Feher M, Cox A, Munro N. Management of hyperglycaemia in type 2 diabetes: a clinician's algorithm. Br J Diab Vas Dis 2008; 8: 3-4.